Tandem Diabetes Care reports data for hybrid closed-loop insulin pump
Tandem Diabetes Care touted data last week at the American Diabetes Association 79th Scientific Sessions in San Francisco from two studies of its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.
Participants in the International Diabetes Closed Loop Protocol-3 study using the Control-IQ technology for six months had a time in range of 71% per day compared to the 59% per day for participants using sensor-augmented pump (SAP) therapy alone. Time spent with glucose values above 180 mg/dL was 27% in participants using Control-IQ and 39% in the group using SAP therapy. Time spent with glucose levels below 70 mg/dL was 1.4% using Control-IQ and 1.9% with SAP therapy.
“The contributions of the iDCL Trial to the body of automated insulin delivery research and its implications for the future of closed-loop technology is invaluable to the diabetes community,” said Dr. Boris Kovatchev, principal investigator of the iDCL Trials. “The NIH has provided an incredible service with their forward-thinking approach and support for this enormous undertaking.”
The Freelife Kid AP study showed an increase of time in range from 60% to 72% per day in participants using the Control-IQ technology with 83% during the overnight period. There was a reduction of time spent with glucose levels above 180 mg/dL from 36% to 25% and time spent below 70 mg/dL from 4% to 3%. No severe hypoglycemia was reported in the study.
“Waking up with glucose levels in control decreases the risk of both high and low blood glucose throughout the entire day, so the improvements in time in range seen in these studies using Control-IQ technology, particularly in the overnight period, are extremely compelling,” Dr. Eric Renard, principal investigator for the Freelife Kid AP study, said in a press release. “But not only do new hybrid closed-loop systems need to be effective at improving glycemic control, but they must also be easy to understand and use so patients can experience the full benefits of the technology. The t:slim X2 insulin pump with Control-IQ technology easily achieved both of these objectives.”
The t:slim X2 insulin pump with Control-IQ technology uses the Dexcom G6 continuous glucose monitoring sensor to predict glucose levels and adjust insulin delivery as needed while also allowing the user to manually bolus for meals.
